Abbott’s FreeStyle Libre continuous glucose monitoring technology is associated with a significant reduction in the risk of hospitalization for heart complications in people with diabetes, according ...

Abbott announced results from its REFLECT real-world studies that show the use of FreeStyle Libre continuous glucose monitoring (CGM) technology is associated with a significant reduction in the risk ...

Abbott Laboratories (NYSE:ABT) recently shared findings from its REFLECT real-world studies, revealing that the use of its FreeStyle Libre® continuous glucose monitoring (CGM) system is linked to a ...

Abbott's wearable FreeStyle Libre 3 device – which is billed as the smallest and thinnest real-time CGM system available – sends glucose readings every minute directly to the user's smartphone ...